UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): March 31, 2017
Argos Therapeutics, Inc.
(Exact Name of Registrant as Specified in Charter)
| | | |
| Delaware | 001-35443 | 56-2110007 |
(State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
| | |
4233 Technology Drive Durham, North Carolina 27704 | |
| (Address of Principal Executive Offices) | |
Registrant’s telephone number, including area code: (919) 287-6300
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| | ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| | ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| | ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| | ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 5.02 | | Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers |
(b) On March 31, 2017, Ralph Snyderman, M.D. voluntarily resigned from Argos Therapeutics, Inc.’s (the "Company") Board of Directors (“the Board”), effective as of that date. There were no disagreements between Dr. Snyderman and the Company or any officer or director of the Company which led to Dr. Snyderman’s resignation. Dr. Snyderman had served on the Board since December 2016. With the resignation, Dr. Snyderman also resigned as a member of the Company’s Audit Committee.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | ARGOS THERAPEUTICS, INC. | |
| | | | |
| | By: | /s/ Jeffrey D. Abbey | |
| | Name: | Jeffrey D. Abbey | |
| | Title: | President and Chief Executive Officer |
DATED: April 4, 2017
